Related references
Note: Only part of the references are listed.How I treat acute lymphoblastic leukemia in older adolescents and young adults
Emily Curran et al.
BLOOD (2015)
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study
Ching-Hon Pui et al.
LANCET ONCOLOGY (2015)
A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia
Anthony V. Moorman et al.
BLOOD (2014)
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
Kheira Beldjord et al.
BLOOD (2014)
The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Yi Zhou et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Postinduction Minimal Residual Disease Monitoring by Polymerase Chain Reaction in Children With Acute Lymphoblastic Leukemia
Maddalena Paganin et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Outcomes of Children With BCR-ABL1-Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease
Kathryn G. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
Josep-Maria Ribera et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
Ajay Vora et al.
LANCET ONCOLOGY (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Detection and management of minimal residual disease in acute lymphoblastic leukemia
Martin Schrappe
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2012)
Has MRD monitoring superseded other prognostic factors in adult ALL?
Monika Brueggemann et al.
BLOOD (2012)
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
Nicola Goekbuget et al.
BLOOD (2012)
Minimal Residual Disease-Guided Treatment Deintensification for Children With Acute Lymphoblastic Leukemia: Results From the Malaysia-Singapore Acute Lymphoblastic Leukemia 2003 Study
Allen Eng Juh Yeoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Modern Therapy of Acute Lymphoblastic Leukemia
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
Patricia Stow et al.
BLOOD (2010)
Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993
Bella Patel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Dario Campana
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2010)
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
Renato Bassan et al.
BLOOD (2009)
Results of the Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Regimen in Elderly Patients With Acute Lymphocytic Leukemia
Susan O'Brien et al.
CANCER (2008)
Outcome of Adults With Acute Lymphocytic Leukemia After Second Salvage Therapy
Susan O'Brien et al.
CANCER (2008)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding et al.
BLOOD (2007)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
Drug therapy - Treatment of acute lymphoblastic leukemia
CH Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular genetics of acute lymphoblastic leukemia
SA Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
HM Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
